Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 30-patient U.K. Phase II dose-ranging trial, Anti-G17 gave an overall median survival of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury